>> I'm not seeing near term catalysts, so trading it technically.<<
Link to trial: Trillium P1
Final readout almost four years from now, but this is a two part trial, with P1a presumably reading out before the midpoint. I'd guess mid 2017. Perhaps management will provide a slightly more educated guess in the near future. They did say there would be an update this year, but whether that's just about enrollment progress or some sort of interim look, I'm not sure. Anyone?
While there will be further preclinical activity, none of it looks like a big catalyst, unless 1) the stock is stupid oversold - umm, check - and a) really good preclinical combo data is revealed or b) they start solid tumor trial(s) earlier than market anticipates. The latter seems less likely near term, while blockbuster preclinical data - :>} - could come out at any time.
First attempt at trading it technically not going well so far, but a small position.
I am tempted to call up and ask if they are seeing any interest in their CD200 program, or if they are talking to anyone at all about it. They keep not talking about it publicly, so is it dead?
Cheers, Tuck |
